Cambodian American chefs are finding success and raising their culture's profile. On their terms
Chef Phila Lorn was not necessarily aiming for 'quote-unquote authentic' Cambodian food when he opened Mawn in his native Philadelphia two years ago. So when he approached some Cambodian teen patrons, he braced himself for questioning.
'Someone's going to say something like, 'That's not how my mom makes her oxtail soup,'' Lorn said. 'So I walk up to the table. I'm like, 'How is everything?' And the kid looks up to me and he goes, 'It doesn't even matter, dude. So glad you're here.''
It was at that moment that Lorn realized Mawn — the phonetic spelling of the Khmer word for 'chicken' — was more than a noodle shop. It meant representation.
In June, he will be representing his dual cultures — Cambodian and Philly — at his first James Beard Awards, as a nominee for Best Emerging Chef. In the food world, it's akin to getting nominated for the Academy Awards.
Cambodian restaurants may not be as commonplace in the U.S. as Chinese takeout or sushi spots. And Cambodian food is often lazily lumped in with the food of its Southeast Asian neighbors, despite its own distinctness. But in recent years, enterprising Cambodian American chefs have come into their own, introducing traditional dishes or putting their own twist on them.
Many of them were raised in families who fled the Khmer Rouge's reign of terror, which began 50 years ago and killed about 1.7 million people. Since then, the Cambodian community in the U.S. has grown and set down roots.
Through food, these chefs are putting the attention back on Cambodian heritage and culture, rather than that traumatic history.
Dr. Leakhena Nou, a sociology professor at California State University, Long Beach who has studied social anxiety among post-Khmer Rouge generations, says the Cambodian diaspora is often seen by others too narrowly through the lens of victimhood. In 2022, she publicly opposed California legislation that focused only on genocide for a K-12 curriculum on Cambodian culture.
'It's a part of their history so they shouldn't run away from it but at the same time they should force others to understand that that's not the only part of their heritage, their historical identity,' she said.
What is Cambodian cuisine?
Cambodian food has sometimes been hastily labeled as a mild mix of Thai and Vietnamese with some Chinese and Indian influence. But, it has its own native spices and flavors that have been used throughout Southeast Asia. Khmer food emphasizes seafood and meats, vegetables, noodles, rice and fermentation. Salty and sour are prevalent tastes, Nou says.
'It's actually a very healthy diet for the most part in terms of fresh vegetables. Cambodians love to eat fresh vegetables dipped with some sauce,' Nou said.
Signature dishes include amok, a fish curry; lok lak, stir-fried marinated beef; and samlar koko, a soup made using seasonal produce. Nou recalls her father making it with pork bone broth, fish, fresh coconut milk, lemongrass, vegetables and even wildflowers.
Cambodian migration to the U.S.
It was a half-century ago, on April 15, 1975, that the communist Khmer Rouge took over Cambodia. For the next four years, an estimated one-quarter of the population was wiped out due to starvation, execution and illness.
Refugees came in waves to the U.S. in the 1970s and 1980s. Most took on low-level entry jobs with few language barriers, Nou said. These included manufacturing, meatpacking and agricultural labor. Many worked in Chinese restaurants and doughnut shops.
The U.S. Cambodian population has jumped 50% in the last 20 years to an estimated 360,000 people, according to the Census 2023 American Community Survey.
Cooking Cambodian American
Lorn's family settled in Philadelphia in 1985. The only child born in the U.S., he was named after the city (but pronounced pee-LAH'). Like a lot of Asian American kids, Lorn was 'the smelly kid' teased for not-American food in his lunch. But, he said, defending his lunchbox made him stronger. And he got the last laugh.
'It's cool now to be 38 and have that same lunchbox (food) but on plates and we're selling it for $50 a plate,' said Lorn, who opened Mawn with wife Rachel after they both had worked at other restaurants.
Indeed, besides popular noodle soups, Mawn has plates like the $60 steak and prohok, a 20-ounce ribeye with Cambodian chimichurri. Prohok is Cambodian fermented fish paste. Lorn's version has lime juice, kulantro, Thai eggplants and roasted mudfish.
It sounds unappetizing, Lorn admits, 'but everyone who takes a piece of rare steak, dips and eats it is just like, 'OK, so let me know more about this food.''
May, which is Asian American Pacific Islander Heritage Month and when Cambodia conducts a Day of Remembrance, is also when Long Beach has Cambodian Restaurant Week. The city is home to the largest concentration of Cambodians outside of Cambodia.
Chad Phuong, operator of Battambong BBQ pop-up, was a participant.
Phuong came to Long Beach as a child after fleeing the Khmer Rouge, which murdered his father. After high school, he worked at a Texas slaughterhouse and learned about cutting meats and barbecue. In 2020, he pivoted from working in the medical field to grilling.
Known as 'Cambodian Cowboy,' he has been profiled locally and nationally for brisket, ribs and other meats using a dry rub with Cambodian Kampot pepper, 'one of the most expensive black peppers in the world.' There's also sausage with fermented rice and sides like coconut corn.
The pitmaster recently started mentoring younger vendors. Contributing to the community feels like building a legacy.
'It just gives me a lot of courage to present my food,' Phuong said. 'We don't need to talk about the past or the trauma. Yes, it happened, but we're moving on. We want something better.'
More Cambodian-run establishments have flourished. In 2023, Lowell, Massachusetts, mayor Sokhary Chau, the country's first Cambodian American mayor, awarded a citation to Red Rose restaurant for being a Beard semifinalist. This year, Koffeteria bakery in Houston, Sophon restaurant in Seattle and chef Nite Yun of San Francisco's Lunette Cambodia earned semifinalist nods.
Lorn, an admirer of San Francisco's Yun, says he still feels imposter syndrome.
'I feel like I'm more Ray Liotta than Nite Yun,' said Lorn. 'Whether we win or not, to me, honestly, I won already.'
Meanwhile, he is preparing to open a Southeast Asian oyster bar called Sao. It's not intended to be Cambodian, just a reflection of him.
'I don't want to be pigeonholed,' Lorn said. 'And it's not me turning from my people. It's just me keeping it real for my people.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
These biotech companies have several catalysts ahead -- and in the past have soared on good news. They both offer innovative candidates that could result in game-changing treatments for patients. 10 stocks we like better than Viking Therapeutics › If you're looking to add growth to your portfolio, biotech stocks can be a great choice. Exciting research is happening in these companies' labs, and in some cases, game-changing treatment candidates are approaching important milestones or even going over the finish line. As an investor in these companies, you can benefit as they report positive clinical trial news, score a regulatory approval, or start generating product revenue. Wall Street considers two candidates extremely compelling right now, with forecasts for potential gains of more than 80% and 200% in the coming 12 months. One of these players is working in the high-growth area of weight loss drugs, and the other candidate showed its strengths by winning the world's first-ever approval of a product based on CRISPR gene editing. Let's check out these two biotech stocks to buy before they skyrocket. Viking Therapeutics (NASDAQ: VKTX) soared early last year when it reported strong data from the phase 2 trial of its weight loss candidate, VK2735, but the stock has since given back those gains and is trading closer to the level it was at prior to that data announcement. Since, the company has continued to advance VK2735 in injectable form and a version in pill form, and demand for these sorts of drugs remains high -- these are two reasons to believe that Viking has the potential to take off again. And catalysts may be on the horizon. The drug works in a manner similar to Eli Lilly's blockbuster tirzepatide, sold under the names Mounjaro and Zepbound. These drugs interact with hormones involved in digestion and have helped people quickly and safely lose weight. Viking is beginning the phase 3 trial for injectable VK2735 in the second quarter and expects data from its phase 2 trial of the pill version in the second half. Any data announcements could result in big moves for the stock, as there is plenty of room for a new company to enter the weight loss drug market -- one forecast to approach $100 billion in a few years. Wall Street is optimistic about Viking's prospects, with the average price forecast predicting an increase of about 240% in the stock price from today's level. Of course, Viking depends heavily on the outcome of these trials, so some risk is involved -- but data have been strong, so growth investors may want to get in on Viking now to potentially post a big win later. CRISPR Therapeutics (NASDAQ: CRSP) stock surged in the year leading up to a major milestone: its first product approval. But since last year's launch of Casgevy, a gene-editing treatment for blood disorders, the stock has been on the decline. Sometimes, investors buy a stock well before the company wins approval or launches a product, then lock in gains after the good news lands -- and I think this is what's happened here. But what this does is offer us a chance to get in at a very good price on a promising company that could deliver fantastic news down the road. Casgevy, as a gene-editing treatment, requires a longer time to roll out than a pill or injection, as it includes several steps that happen over a period of months. The company recently said new patient initiations should increase "significantly" this year -- so there's reason to be optimistic about revenue growth ahead. CRISPR Therapeutics also recently reported positive phase 1 data for a gene editing candidate addressing the problem of high cholesterol. And the company expects to report data soon from a phase 1 trial of a candidate targeting patients with elevated levels of lipoprotein(a) -- a risk factor for cardiovascular events. These could represent huge markets for CRISPR Therapeutics if the candidates reach the finish line, and in the meantime, any potential positive news could boost the stock. The company also expects other trial updates in candidates for oncology and autoimmune diseases this year -- so this biotech's calendar is full of possible catalysts. Wall Street's average price forecast calls for an 84% gain for CRISPR Therapeutics from today's price -- if all goes well in clinical trials and Casgevy starts to show revenue growth, now could represent a golden buying opportunity for growth investors. Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CRISPR Therapeutics. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy. 2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
35 minutes ago
- Yahoo
Dan Ives Says Market Is 'Massively Underestimating' This AI Play, Urges Investors To Look Beyong Mag 7
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Dan Ives' new artificial intelligence exchange-traded fund (ETF) holds securities beyond the Magnificent 7 stocks, as he believes in looking past valuations for investments in the technology sector. What Happened: The Dan IVES Wedbush AI Revolution ETF (NYSE:IVES), managed by the Wedbush analyst, started trading on June 4, earlier this month. Ives boasts of the fund by saying that it just doesn't have the top four, five Magnificent 7 names, but stocks which investors wouldn't even thematically consider as an AI name today. "I believe the market is still massively underestimating what the growth is going to look like for the AI revolution in tech," he told CNBC. Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — According to him, tech trade remains significant even for the investors who missed out on its growth in the past few years. "If you focus just on valuation, you miss every transformational tech stock of the last 20 years," Ives said. Ives says Oracle Corp. (NYSE:ORCL) will be the 'epicenter' of the AI theme, while highlighting other 'AI 30' stocks which are part of his fund. Palantir Technologies Inc. (NASDAQ:PLTR), International Business Machines Corp. (NYSE:IBM), Salesforce Inc. (NYSE:CRM), SoundHound AI Inc. (NASDAQ:SOUN), and Innodata Inc. (NASDAQ:INOD) are a few notable names that are a part of his ETF's 'AI 30' basket. Microsoft Corp. (NASDAQ:MSFT), Nvidia Corp. (NASDAQ:NVDA), and Broadcom Inc. (NASDAQ:AVGO) are the top three holdings of the IVES It Matters: The 'AI 30' stocks, which are a part of the IVES ETF, hold the AI plays from multiple industries. They include hyperscalers, cybersecurity, consumer platforms, and robotics. According to Ives, the list was compiled from his deep dives into major AI players. The ETF has $183 million in assets under management as of June 17 close. Ives said that the AI space was experiencing a "golden age." The Dan IVES Wedbush AI Revolution ETF has risen by 2.76% since its inception. A comparable index, S&P Kensho Global Artificial Intelligence Enablers, rose 6.08% on a month-to-date basis. Meanwhile, the SPDR S&P 500 ETF Trust (NYSE:SPY) and Invesco QQQ Trust ETF (NASDAQ:QQQ), which track the S&P 500 index and Nasdaq 100 index, respectively, declined slightly on Wednesday. The SPY was down 0.015% at $597.44, while the QQQ was 0.017% lower at $528.99, according to Benzinga Pro data. Read Next: Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. Back a bold new approach to cancer treatment with high-growth potential. If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends would you invest in it? Photo courtesy: Shutterstock This article Dan Ives Says Market Is 'Massively Underestimating' This AI Play, Urges Investors To Look Beyong Mag 7 originally appeared on
Yahoo
40 minutes ago
- Yahoo
Christina Bohannan makes third run for Iowa's 1st Congressional District
Jun. 21—History shows that just because a candidate makes multiple attempts to win an election doesn't mean they can't eventually pull through. U.S. Rep. Mariannette Miller-Meeks lost a number of times to Dave Loebsack before winning Iowa's 1st Congressional District seat in a close 2020 election. Now her past Democratic challenger, Christina Bohannan, is attempting the same thing for the 2026 election cycle, provided she is the favorite in the primary. On June 17, Bohannan announced her campaign to take on Miller-Meeks once again. In a press release, her campaign said Bohannan nearly defeated Miller-Meeks in 2024 — less than 800 votes decided the election — and that the Democrat "outworked, outraised and outmatched her." Bohannan said, "Mariannette Miller-Meeks has had three terms in Congress — three chances to do right by the people of Iowa. Instead, she has taken over $4 million from corporate special interests and done nothing but vote their way. And she has put partisan politics over Iowans again and again. From cutting billions of dollars from Medicaid in the Trump Administration's One Big Beautiful Bill, to siding with DOGE's cuts to Social Security and enabling unelected, unaccountable billionaires like Elon Musk, Bohannan said the Republican congresswoman has forgotten about her constituents. "It's time someone put Iowa first," Bohannan said. Bohannan went on to say Miller-Meeks needs to explain "why she keeps putting Washington special interests first." The Democratic challenger claimed Miller-Meeks supported Trump's One Big Beautiful Bill, repeatedly voted for cost-increasing tariffs and is a member of the DOGE Caucus. Bohannan previously worked as an engineer and taught at the University of Iowa College of Law for 20 years. She also worked as an elected legislator for the Iowa House, defeating a 20-year incumbent in District 85. Bohannan is running for Congress because she believes in a government that works for the people. In May, another Democrat announced he would be running for Iowa's 1st Congressional District. Bob Krause, a former legislator who also tried running for U.S. Senate, announced his campaign with the slogan "Flip The House With Krause." Krause said Miller-Meeks votes "like Trump's rubber stamp." Travis Terrell, a Democrat from Johnson County, also announced his bid for Iowa's 1st Congressional District race. His campaign page on Facebook notes he is a working-class, New Deal Democrat fighting for healthcare, fair wages and a government that serves other working-class people and not billionaires. In addition to Miller-Meeks likely running for the seat, fellow Republican and former primary challenger David Pautsch announced in February that he would also be running for the seat. Pautsch touts himself as a MAGA Republican. He has been critical of Miller-Meeks, saying she is not conservative enough.
